4ZU Stock Overview A clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Biora Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Biora Therapeutics Historical stock prices Current Share Price US$5.10 52 Week High US$15.50 52 Week Low US$3.88 Beta 1.37 1 Month Change 0% 3 Month Change -1.92% 1 Year Change -54.87% 3 Year Change -98.44% 5 Year Change n/a Change since IPO -99.18%
Recent News & Updates
Biora Therapeutics, Inc.(OTCPK:BIOR) dropped from S&P TMI Index Dec 13
Biora Therapeutics, Inc.(OTCPK:BIOR) dropped from NASDAQ Composite Index Dec 11
Biora Therapeutics Receives Formal Notice from the Nasdaq Stock Market Dec 10
Biora Therapeutics Provides Non-Compliance Update Nov 16
Biora Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08 Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000002 million. Oct 29
See more updates
Biora Therapeutics, Inc.(OTCPK:BIOR) dropped from S&P TMI Index Dec 13
Biora Therapeutics, Inc.(OTCPK:BIOR) dropped from NASDAQ Composite Index Dec 11
Biora Therapeutics Receives Formal Notice from the Nasdaq Stock Market Dec 10
Biora Therapeutics Provides Non-Compliance Update Nov 16
Biora Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08 Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000002 million. Oct 29
Athyrium Capital Engages in Discussions with Biora Therapeutics Sep 13 Biora Therapeutics Announces Positive Nasdaq Listing Decision Aug 28
Athyrium Capital Management Engages with Biora Therapeutics Aug 15
Second quarter 2024 earnings released: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023) Aug 13
Biora Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 09
Biora Therapeutics, Inc. Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented At KOL Event Jul 18
Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc Jul 09
Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600 Jul 01
Biora Therapeutics Provides Non-Compliance Update Jun 15
Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director Jun 08
First quarter 2024 earnings released: US$0.14 loss per share (vs US$1.59 loss in 1Q 2023) May 17
Biora Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024 May 09
Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose (Mad) Cohorts for Clinical Trial of BT-600 Apr 30
Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024 Apr 26
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development Apr 05 Athyrium Capital Management Engages in Discussions with Biora Therapeutics Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million. Apr 02
Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million. Apr 01
Full year 2023 earnings released: US$7.88 loss per share (vs US$6.40 loss in FY 2022) Mar 28
Biora Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024 Mar 19
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose (Sad) Cohorts of Phase 1 Clinical Study of BT-600 Feb 27
Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600 Jan 09
Athyrium Capital Management Engages in Discussions with Biora Therapeutics Dec 21
Biora Therapeutics Receives Non-Compliance Notice from Nasdaq Dec 16
Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis Dec 01
Third quarter 2023 earnings released: US$4.89 loss per share (vs US$1.99 loss in 3Q 2022) Nov 15
Biora Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 07
Biora Therapeutics Presents Data on the Biojet™ Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes Oct 06
Biora Therapeutics, Inc. (NasdaqGM:BIOR) acquired Interface Therapeutics Inc. Sep 13
Biora Therapeutics Progresses Its BioJet™ Systemic Oral Delivery Platform Sep 07
New major risk - Financial position Aug 17
First half 2023 earnings released: US$3.01 loss per share (vs US$2.79 loss in 1H 2022) Aug 16
Biora Therapeutics, Inc. Announces New Patents Covering Its BioJet Systemic Oral Delivery Platform Aug 04
Biora Therapeutics, Inc. Announces Clinical Device Performance Study Results for its NaviCap Targeted Oral Delivery Platform Jul 28
Biora Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Jul 16
An unknown large diagnostics company acquired Legacy Diagnostics Assets of Biora Therapeutics, Inc. (NasdaqGM:BIOR). Jul 06
High number of new and inexperienced directors Jun 30
Biora Therapeutics Announces New Patents for Its NaviCap Targeted Oral Delivery Platform Jun 29
Biora Therapeutics Presents Data on the BioJet Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions Jun 27 Biora Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million. Jun 16
Biora Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023 May 09
Biora Therapeutics Announces Improved Bioavailability Results for Its Systemic Delivery Platform Feb 17
Biora Therapeutics Receives Compliance Letter from Nasdaq Jan 23
Biora Therapeutics, Inc. Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress Jan 21
Biora Therapeutics, Inc. Receives Feedback from the United States Food and Drug Administration on Its Clinical Development Plans for Its Pgn-600 Program Jan 10
Biora Therapeutics Receives Non-Compliance Notice from Nasdaq Dec 12
Athyrium Capital Engages in Discussions with Biora Therapeutics Nov 19
Third quarter 2022 earnings released: US$0.08 loss per share (vs US$0.39 loss in 3Q 2021) Nov 17
High number of new and inexperienced directors Nov 16 Biora Therapeutics, Inc. has completed a Follow-on Equity Offering. Nov 11
Biora Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 08
Biora Therapeutics, Inc. Shares Data from Device Performance Study in Ulcerative Colitis Patients Oct 26
Biora Therapeutics, Inc. Shares Preclinical Data on Oral Delivery of Biologics At the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference Oct 20
Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board Sep 08
Biora Therapeutics, Inc. Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for Its Targeted Therapeutics Platform Aug 11
Biora Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 09
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for Its Targeted Therapeutics Platform Jul 08
Biora Therapeutics, Inc. Announces Board Appointment Jun 16
Biora Therapeutics Receives Non-Compliance Notice from Nasdaq Jun 11
First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.30 loss in 1Q 2021) May 12
Biora Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
High number of new and inexperienced directors Apr 27
Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations Apr 26
Full year 2021 earnings released: US$1.86 loss per share (vs US$7.01 loss in FY 2020) Mar 30
Progenity, Inc. Announces Departure of Damon Silvestry Feb 18
Progenity, Inc. has completed a Follow-on Equity Offering in the amount of $40 million. Aug 20 Progenity, Inc.(NasdaqGM:PROG) dropped from Russell 2500 Growth Index Shareholder Returns 4ZU DE Biotechs DE Market 7D 0% -1.9% 3.5% 1Y -54.9% -4.2% 13.1%
See full shareholder returns
Return vs Market: 4ZU underperformed the German Market which returned 9.4% over the past year.
Price Volatility Is 4ZU's price volatile compared to industry and market? 4ZU volatility 4ZU Average Weekly Movement n/a Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 4ZU's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 4ZU's volatility change over the past year.
About the Company Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Show more Biora Therapeutics, Inc. Fundamentals Summary How do Biora Therapeutics's earnings and revenue compare to its market cap? 4ZU fundamental statistics Market cap €649.39k Earnings (TTM ) -€34.82m Revenue (TTM ) €873.09k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4ZU income statement (TTM ) Revenue US$892.00k Cost of Revenue US$0 Gross Profit US$892.00k Other Expenses US$36.47m Earnings -US$35.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -8.04 Gross Margin 100.00% Net Profit Margin -3,988.12% Debt/Equity Ratio -36.9%
How did 4ZU perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/14 20:16 End of Day Share Price 2024/10/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Biora Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Julian Harrison BTIG Joseph Pantginis H.C. Wainwright & Co.
Show 4 more analysts 